{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-25-000109","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.843547+00:00","generated_at":"2026-05-16T20:53:56.967773+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MacroGenics Q3 net income $16.8M on $72.8M revenue; ends lorigerlimab prostate study; secures $75M partnership payments","bullets":["Net income $16.8M ($0.27 diluted EPS) vs $56.3M ($0.90) in Q3 2024; revenue $72.8M down from $110.7M.","Discontinued lorigerlimab in prostate cancer (LORIKEET) after interim data; continues LINNET ovarian study, update by mid-2026.","Received $75M in new partnership payments: $50M from Sanofi (TZIELD milestones), $25M from Gilead (new preclinical program).","Cash $146.4M at Sep 30, expected to add $75M in Q4; runway extended into late 2027.","Three ADC programs advancing: MGC026 started Phase 1 expansion, MGC028 in Phase 1 dose escalation, MGC030 IND planned 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-25-000109","json":"https://secwatch.observer/filing/0001125345-25-000109.json","markdown":"https://secwatch.observer/filing/0001125345-25-000109.md","text":"https://secwatch.observer/filing/0001125345-25-000109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/0001125345-25-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534525000109/mgnx-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:53:56.967773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}